MIRM Stock: Price, Earnings History and SEC Filings
Mirum Pharmaceuticals, Inc. (MIRM) last traded at $85.00, down 1.61% on the latest session and down 0.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.80 against an analyst estimate of $-0.77, a miss of 3.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MIRM earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.80 | $-0.77 | -3.90% |
| Mar 2026 | May 6, 2026 | $-0.39 | $-0.40 | +2.50% |
| Dec 2025 | Feb 25, 2026 | $-0.11 | $0.02 | -650.00% |
| Sep 2025 | Nov 4, 2025 | $0.05 | $-0.10 | +150.00% |
MIRM beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How MIRM reacts to earnings
Across its last 8 earnings releases, MIRM moved 8.3% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | -11.04% |
| 2026-05-06 | After close | -6.50% |
| 2026-02-25 | After close | -15.13% |
| 2026-01-12 | Before open | +3.38% |
| 2025-11-04 | After close | -1.24% |
| 2025-08-06 | After close | +12.04% |
| 2025-05-07 | After close | +9.75% |
| 2025-02-26 | After close | -7.02% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
MIRM financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $521M | -$23M | $55M | -4.5% | $-0.47 |
| 2024 | $337M | -$88M | $9M | -26.1% | $-1.85 |
| 2023 | $186M | -$163M | -$71M | -87.7% | $-4.00 |
| 2022 | $77M | -$136M | -$120M | -176.0% | $-4.02 |
| 2021 | $19M | -$84M | -$133M | -438.9% | $-2.77 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for MIRM
- 8-K · Oct 26, 2026Other events
- 8-K · Oct 13, 2026Other events
- 8-K · Sep 28, 2026Other events
- 8-K · Sep 8, 2026Officer or director change
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 18, 2026Shareholder vote
- 8-K · May 18, 2026Material agreement, New financial obligation, Unregistered share sale
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
Insider filing activity
MIRM insiders filed 10 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
MIRM news
- AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?Oct 31, 2026 · finance.yahoo.com
- Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 28, 2026 · finance.yahoo.com
- Mirum Pharmaceuticals (MIRM) Stock Trades Near Fair Value As Pediatric FOP Study ProgressesOct 28, 2026 · finance.yahoo.com
- Mirum Pharmaceuticals (MIRM) Could Be 44% Undervalued On Pediatric FOP Trial DataOct 28, 2026 · finance.yahoo.com
- Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026Oct 27, 2026 · finance.yahoo.com
- Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 27, 2026 · finance.yahoo.com
- Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans ProgressivaOct 26, 2026 · finance.yahoo.com
- Mirum Pharmaceuticals to Participate in Upcoming Investor ConferencesOct 21, 2026 · finance.yahoo.com
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. (MIRM) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.